NCT04677114View on ClinicalTrials.gov

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

March 6, 2025

Study Completion Date

March 6, 2025

Conditions
Drug UseOpioid-use Disorder
Interventions
DRUG

Buprenorphine and Outpatient Parenteral Antibiotic Therapy

Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.

DRUG

Buprenorphine and standard of care antibiotic treatment

All participants will receive treatment of OUD and the infection per usual clinical care.

Trial Locations (1)

40515

University of Kentucky, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Laura Fanucchi

OTHER

NCT04677114 - Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections | Biotech Hunter | Biotech Hunter